目的 对基础胰岛素胰高糖素样肽-1(Glucagon like peptide-1,GLP-1)受体激动剂德谷胰岛素利拉鲁肽注射液(Insulin Degludec and Lira-glutide Injection,IDegLira)进行多维度综合评价,为医疗机构遴选药品提供科学依据.方法 基于《中国医疗机构药品评价与遴选快速指南(第二版)》(下称《快速指南(第二版)》)的评价维度、评价细则及评价方法,对IDegLira进行药品评价.结果 根据《快速指南(第二版)》,IDegLira的总评分为61.95分;其中,药学特性21.5分,有效性17.56分,安全性15.12分,经济性3.47分,其他指标4.3分.结论 根据当前药品情况评分,IDegLira的推荐意见为弱推荐.《快速指南(第二版)》能帮助医疗机构快速地评价与遴选药品,有在医疗机构推广的潜力和价值.
Multi-Dimensional Quantitative Evaluation of IDegLira Based on the"A Quick Guideline for Drug Evaluation and Selection in Chinese Medical In-stitutions(the Second Edition)"
OBJECTIVE To evaluate the basal insulin glucagon-like peptide-1(Glucagon like peptide-1,GLP-1)receptor agonist insulin liraglutide injection(Insulin Degludec and Liraglutide Injection,IDegLira)as the sam-ple,to provide reference for medical institutions to select drugs.METHODS Based on the evaluation dimensions,e-valuation rules and evaluation methods in Chinese Medical Institutions(second Edition),IDegLira was evaluated for drugs.RESULTS According to the Quick Guide(Second Edition),the total score of IDegLira was 61.95 points;21.5 points for pharmacy,17.56points for effectiveness,15.12 points for safety,3.47 points for economy and 4.3 points for other indicators.CONCLUSION According to the current drug situation score,the IDegLira recommen-dation is a weak recommendation.The Quick Guide(second Edition)can help medical institutions to quickly evalu-ate and select drugs,which has the potential and value of promotion in medical institutions.
万方数据
维普
